BioCentury | Jan 8, 2021
Finance

Jan. 8 Quick Takes: Venture rounds for Abbisko, DiCE, Aulos, LifeMine, Mana, Theolytics and more

Carlyle leads Abbisko’s $123M series DShanghai-based oncology company Abbisko Therapeutics Co. Ltd. raised $123 million in a series D round led by the Carlyle Group. The company named Warburg Pincus, OrbiMed, Lake Bleu Capital and an...
BioCentury | Dec 31, 2020
Distillery Therapeutics

Host-directed inhibitors against the SKI complex to inhibit coronavirus, influenza, Ebola, Marburg viruses

...MERS-CoV) strains. In silico screening of ~780,000 compounds for molecules predicted to bind at the interface...
BioCentury | Dec 5, 2020
Translation in Brief

James Wilson developing gene therapy version of Regeneron COVID mAb cocktail; plus an oncolytic adenovirus, MapLight-Michael J. Fox Foundation and more

...Charité-Universitätsmedizin Berlin researchers showed that SARS-CoV-2 can enter the CNS by crossing the olfactory neural-mucosal interface...
BioCentury | Nov 20, 2020
Finance

Nov. 19 Quick Takes: Olema’s IPO, plus venture rounds for Imago, Medable,  China deal for AUM-Newsoara and Qiming’s $1.2B fund

Olema posts big gain after $209M IPOShares of Olema Pharmaceuticals Inc. (NASDAQ:OLMA) rose $30 (158%) to $49 in their first day of trading after the company raised $209 million through the sale of 11 million...
BioCentury | Oct 27, 2020
Distillery Therapeutics

UCSF team develops trivalent binder of SARS-CoV-2 spike for COVID-19

...compounds capable of binding multiple epitopes on SARS-CoV-2 S, including those at the ACE2 binding interface...
BioCentury | Sep 11, 2020
Product Development

Pfizer’s MacKenzie: Other diseases deserve the same acceleration as COVID-19: a BioCentury audio interview

...I would highlight is that in the interface...
BioCentury | Sep 9, 2020
Product Development

Networking that fueled COVID-19 response should spill into digital sciences and more, says Genmab’s van de Winkel: a BioCentury audio interview

Jan van de Winkel sees a strong future for data sharing and more master protocol trials, fueled by increasing adoption of digital sciences, as companies turn the collaboration they’ve shown in COVID-19 into longer-term productive...
BioCentury | Aug 25, 2020
Management Tracks

Former head of gRED Varney joining Erasca; plus AAM, City of Hope, Immunovant, Kura, Illumina and more

...Department of Biochemistry at University of Iowa. It is the first research department focused on the interface...
BioCentury | Aug 5, 2020
Emerging Company Profile

Nura reveals neuroprotective lead target, first part of its neurology one-two punch

...Nura’s neuroinflammation targets will come from Freeman’s lab, which is discovering targets within the axon-glial interface...
...wide range of in vivo and ex vivo models of axonal degeneration and the axon-glial interface...
BioCentury | Jun 19, 2020
Deals

In-depth M&A analysis in a new BioCentury format: Letter from the Editor

...latest addition to the ways we provide insight, a presentation format that provides a simple interface...
Items per page:
1 - 10 of 293
BioCentury | Jan 8, 2021
Finance

Jan. 8 Quick Takes: Venture rounds for Abbisko, DiCE, Aulos, LifeMine, Mana, Theolytics and more

Carlyle leads Abbisko’s $123M series DShanghai-based oncology company Abbisko Therapeutics Co. Ltd. raised $123 million in a series D round led by the Carlyle Group. The company named Warburg Pincus, OrbiMed, Lake Bleu Capital and an...
BioCentury | Dec 31, 2020
Distillery Therapeutics

Host-directed inhibitors against the SKI complex to inhibit coronavirus, influenza, Ebola, Marburg viruses

...MERS-CoV) strains. In silico screening of ~780,000 compounds for molecules predicted to bind at the interface...
BioCentury | Dec 5, 2020
Translation in Brief

James Wilson developing gene therapy version of Regeneron COVID mAb cocktail; plus an oncolytic adenovirus, MapLight-Michael J. Fox Foundation and more

...Charité-Universitätsmedizin Berlin researchers showed that SARS-CoV-2 can enter the CNS by crossing the olfactory neural-mucosal interface...
BioCentury | Nov 20, 2020
Finance

Nov. 19 Quick Takes: Olema’s IPO, plus venture rounds for Imago, Medable,  China deal for AUM-Newsoara and Qiming’s $1.2B fund

Olema posts big gain after $209M IPOShares of Olema Pharmaceuticals Inc. (NASDAQ:OLMA) rose $30 (158%) to $49 in their first day of trading after the company raised $209 million through the sale of 11 million...
BioCentury | Oct 27, 2020
Distillery Therapeutics

UCSF team develops trivalent binder of SARS-CoV-2 spike for COVID-19

...compounds capable of binding multiple epitopes on SARS-CoV-2 S, including those at the ACE2 binding interface...
BioCentury | Sep 11, 2020
Product Development

Pfizer’s MacKenzie: Other diseases deserve the same acceleration as COVID-19: a BioCentury audio interview

...I would highlight is that in the interface...
BioCentury | Sep 9, 2020
Product Development

Networking that fueled COVID-19 response should spill into digital sciences and more, says Genmab’s van de Winkel: a BioCentury audio interview

Jan van de Winkel sees a strong future for data sharing and more master protocol trials, fueled by increasing adoption of digital sciences, as companies turn the collaboration they’ve shown in COVID-19 into longer-term productive...
BioCentury | Aug 25, 2020
Management Tracks

Former head of gRED Varney joining Erasca; plus AAM, City of Hope, Immunovant, Kura, Illumina and more

...Department of Biochemistry at University of Iowa. It is the first research department focused on the interface...
BioCentury | Aug 5, 2020
Emerging Company Profile

Nura reveals neuroprotective lead target, first part of its neurology one-two punch

...Nura’s neuroinflammation targets will come from Freeman’s lab, which is discovering targets within the axon-glial interface...
...wide range of in vivo and ex vivo models of axonal degeneration and the axon-glial interface...
BioCentury | Jun 19, 2020
Deals

In-depth M&A analysis in a new BioCentury format: Letter from the Editor

...latest addition to the ways we provide insight, a presentation format that provides a simple interface...
Items per page:
1 - 10 of 293